BCDA BioCardia
- 0.396
- +0.005+1.23%
- 0.402
- +0.006+1.39%
BioCardia News
10-Q: Quarterly report
BioCardia Q1 EPS $(0.09) Up From $(0.17) YoY, Sales $55.00K Down From $64.00K YoY
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.09) per share. This is a 47.06 percent increase over losses of $(0.17) per share from the same period last year. The company reported $55.00 t
Press Release: BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-der
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced
BioCardia Announced The Primary Endpoint Results Of The Open Label Roll-in Cohort Of The Cardiamp Cell Therapy In Chronic Myocardial Ischemia Trial
BioCardia Announced The Primary Endpoint Results Of The Open Label Roll-in Cohort Of The Cardiamp Cell Therapy In Chronic Myocardial Ischemia Trial
BioCardia Reveals Promising CardiAMP Trial Results in Webcast
BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the
BioCardia Completes Enrollment Of CardiAMP Cell Therapy For Treatment Of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
BioCardia Completes Enrollment Of CardiAMP Cell Therapy For Treatment Of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
BioCardia(BCDA.US) Officer Buys US$1,012.83 in Common Stock
$BioCardia(BCDA.US)$ Officer Altman Peter purchased 2,750 shares of common stock on Apr 19, 2024 at an average price of $0.3683 for a total value of $1,012.83.Source: Announcement What is statement of
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
BioCardia Full Year 2023 Earnings: Misses Expectations
BioCardia(BCDA.US) Officer Buys US$195 in Common Stock
$BioCardia(BCDA.US)$ Officer Altman Peter purchased 500 shares of Common Stock on Mar 28, 2024 at an average price of $0.39 for a total value of $195.Source: Announcement What is statement of changes
Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference
The following is a summary of the BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript:Financial Performance:BioCardia's revenues fell to $0.5 million in 2023 from $1.4 million in the previous year
BioCardia: Q4 Earnings Insights
BioCardia (NASDAQ:BCDA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:00 AM.Here's what investors need to know about the announcement.EarningsBioCardia beat estimated earnings by
BioCardia Q4 EPS $(0.09) Beats $(0.11) Estimate, Sales $13.00K Miss $90.00K Estimate
BioCardia Q4 EPS $(0.09) Beats $(0.11) Estimate, Sales $13.00K Miss $90.00K Estimate
BioCardia 2023 Loss/Shr 55c >BCDA
BioCardia 2023 Loss/Shr 55c >BCDA
Press Release: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia(R), Inc. [Nasdaq: BCDA], a developer of c
BioCardia Ended 2023 With Cash And Cash Equivalents Of $1.1M
BioCardia Ended 2023 With Cash And Cash Equivalents Of $1.1M
Analysis
Price Target
No Data
